Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Third-line diabetes drugs offer comparable results

By Alisdair Stirling

GPs can base choice of third-line diabetes drugs on patient preferences and clinical characteristics as they all achieve comparable levels of blood sugar control, according to a new meta-analysis.

There was no clear difference between insulin, acarbose, glitazones, GLP-1 agonists, and gliptins in the reduction in blood glucose levels when added to a metformin and sulfonylurea regimen, the study showed.

Researchers analysed data from 18 published trials of at least 24 weeks in duration to evaluate the effects of adding a third antihyperglycaemic drug to the treatment of 4,535 adults aged 18 years or older with type 2 diabetes and HbA1c level of 7% or higher who were already receiving treatment with metformin and sulfonylurea.

Compared with placebo, drug classes did not differ in their effect on HbA1c level. Reductions seen ranged from 0.7% for acarbose to 1.1% for insulin.

Study leader Dr Jorge Gross, an endocrinologist at the Hospital de Cl?nicas de Porto Alegre in Brazil said: ‘There is no clear difference in benefit between drug classes when adding a third agent to treatment of patients with type 2 diabetes who are already receiving metformin and a sulfonylurea. The most appropriate option should depend on each patient's clinical characteristics.'

Annals of Internal Medicine. 2011;154:672-679

All third-line diabetes drugs achieved comparable blood sugar reductions

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say